Gene · 7068
Papers3,032
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,032
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The epigenetic circle: feedback loops in the maintenance of cellular memory. | Epigenetics Chromatin | 2025 | 40830515 | PubTator, text mining | PubMed |
| JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer. | J Exp Clin Cancer Res | 2025 | 40826108 | PubTator, text mining | PubMed |
| Exploration of a Class of Aryl Imidazolyl Ureas As Potent Acid Ceramidase Inhibitors for the Treatment of Fibrotic Diseases. | ACS Omega | 2025 | 40821548 | PubTator, text mining | PubMed |
| Integrative snRNA-seq, molecular docking and dynamics simulations identifies Lasmiditan as drug candidate for Alzheimer's disease. | Clin Transl Med | 2025 | 40817596 | PubTator, text mining | PubMed |
| Safety Choice Drivers of the Coming Treatment Options for Non-Cirrhotic Metabolic Steatohepatitis. | Liver Int | 2025 | 40815181 | PubTator, text mining | PubMed |
| The role of microbiota in nonalcoholic fatty liver disease: mechanism of action and treatment strategy. | Front Microbiol | 2025 | 40809055 | PubTator, text mining | PubMed |
| Future potential therapeutics to treat MASH. | Drug Discov Today | 2025 | 40803572 | PubTator, text mining | PubMed |
| Identification and characterization of early human photoreceptor states and cell-state-specific retinoblastoma-related features. | Elife | 2025 | 40767624 | PubTator, text mining | PubMed |
| Discovery of Highly Potent, Selective, and Liver-Targeted THR-β Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis. | J Med Chem | 2025 | 40762270 | PubTator, text mining | PubMed |
| Multigenerational thyroid hormone resistance due to THRβ mutation. | Eur Heart J Case Rep | 2025 | 40761432 | PubTator, text mining | PubMed |
| Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis. | Clin Mol Hepatol | 2025 | 40755009 | PubTator, text mining | PubMed |
| Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials. | Liver Int | 2025 | 40736113 | PubTator, text mining | PubMed |
| Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). | Cureus | 2025 | 40734888 | PubTator, text mining | PubMed |
| MASLD/MASH-New mechanisms and treatments. | Hepatol Commun | 2025 | 40694379 | PubTator, text mining | PubMed |
| Machine Learning-Based Screening of Cosmetic Ingredients Identifies Vat Blue 6 as a Thyroid Hormone Receptor β Disruptor. | Environ Sci Technol | 2025 | 40668138 | PubTator, text mining | PubMed |
| Epigenomic Modulators and Thyroid Hormone Receptor β Agonists: A New Paradigm for Tumor Suppression in Thyroid Cancer. | Endocrinology | 2025 | 40658739 | PubTator, text mining | PubMed |
| Advances in Understanding Adaptive Hemoglobin Concentration at High Altitude. | Am J Hum Biol | 2025 | 40650341 | PubTator, text mining | PubMed |
| Exploring synergistic therapy for metabolic dysfunction-associated steatotic liver disease. | Prz Gastroenterol | 2025 | 40620309 | PubTator, text mining | PubMed |
| Therapeutic horizons in metabolic dysfunction-associated steatohepatitis. | J Clin Invest | 2025 | 40590228 | PubTator, text mining | PubMed |
| Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). | Health Sci Rep | 2025 | 40535518 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7068/papers?page=10